Purpose

Pramipexole (Prami) is renowned as one of the most widely used drugs in the treatment of Parkinson’s disease. This study aimed to prepare slow-release nanofibers of Prami to reduce (or control) the release rate of the drug from the formulation.

Methods

For this purpose, polyvinyl alcohol (PVA)/carboxymethylcellulose (CMC) nanofibers loaded with Prami were fabricated using the electrospinning technique and characterized using scanning electron microscopy (SEM) and infrared spectroscopy (FTIR). A test has been conducted to evaluate the swelling of the formulations and an HPLC method has been used to assess the effect of both co-electrospinning with polycaprolactone (PCL) nanofibers and cross-linking using glutaraldehyde (GA) vapors on the release kinetics.

Results

The results showed that the co-electrospun nanofibers cross-linked by 12-h exposure to GA vapor exhibited slow release compared to non-hybrid and non-cross-linked fibers. The cell viability assay using the MTT test showed that the nanofibers were cytocompatibility regarding SFIF-PI 44 cell line. The hybrid cross-linked nanofibers were placed in the gelatin shell capsule, and the dissolution profile of the drug in the capsules was investigated.

Conclusions

These results indicated that using nanofibers as the carrier encapsulated in the conventional capsule dosage form can be considered as a new formulation to reduce the used excipients and ease of production.

中文翻译：

---

负载普拉克索的缓释纳米纤维的制备和评价作为一种新型口服给药系统：亲水性和疏水性聚合物的杂交

目的

普拉克索（Prami）被誉为治疗帕金森病最广泛使用的药物之一。本研究旨在制备缓释普拉米纳米纤维，以降低（或控制）药物从制剂中的释放速率。

方法

为此，使用静电纺丝技术制造了负载有普拉米的聚乙烯醇 (PVA)/羧甲基纤维素 (CMC) 纳米纤维，并使用扫描电子显微镜 (SEM) 和红外光谱 (FTIR) 对其进行了表征。已经进行了一项测试来评估制剂的溶胀，并使用 HPLC 方法来评估与聚己内酯 (PCL) 纳米纤维的共静电纺丝和使用戊二醛 (GA) 蒸气交联对释放动力学的影响。

结果

结果表明，与非混合和非交联纤维相比，通过 12 小时暴露于 GA 蒸汽交联的共电纺纳米纤维表现出缓慢的释放。使用 MTT 测试的细胞活力测定表明，纳米纤维对 SFIF-PI 44 细胞系具有细胞相容性。将混合交联纳米纤维置于明胶壳胶囊中，研究药物在胶囊中的溶出曲线。

结论

这些结果表明，使用纳米纤维作为载体封装在常规胶囊剂型中，可以被认为是一种减少辅料使用和易于生产的新剂型。